HRP20161208T1 - Derivati benzilidengvanidina i terapeutska upotreba za liječenje bolesti zbog pogrešnog savijanja proteina - Google Patents

Derivati benzilidengvanidina i terapeutska upotreba za liječenje bolesti zbog pogrešnog savijanja proteina Download PDF

Info

Publication number
HRP20161208T1
HRP20161208T1 HRP20161208TT HRP20161208T HRP20161208T1 HR P20161208 T1 HRP20161208 T1 HR P20161208T1 HR P20161208T T HRP20161208T T HR P20161208TT HR P20161208 T HRP20161208 T HR P20161208T HR P20161208 T1 HRP20161208 T1 HR P20161208T1
Authority
HR
Croatia
Prior art keywords
alkyl
compound
aryl
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
HRP20161208TT
Other languages
English (en)
Croatian (hr)
Inventor
Philippe Guedat
Anne Bertolotti
Original Assignee
Medical Research Council
Inflectis Bioscience
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Research Council, Inflectis Bioscience filed Critical Medical Research Council
Publication of HRP20161208T1 publication Critical patent/HRP20161208T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D253/00Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/061,2,4-Triazines
    • C07D253/0651,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/071,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D253/075Two hetero atoms, in positions 3 and 5
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/155Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/16Compounds containing any of the groups, e.g. aminoguanidine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/16Compounds containing any of the groups, e.g. aminoguanidine
    • C07C281/18Compounds containing any of the groups, e.g. aminoguanidine the other nitrogen atom being further doubly-bound to a carbon atom, e.g. guanylhydrazones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61Halogen atoms or nitro radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HRP20161208TT 2013-01-10 2014-01-10 Derivati benzilidengvanidina i terapeutska upotreba za liječenje bolesti zbog pogrešnog savijanja proteina HRP20161208T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1300435.3A GB201300435D0 (en) 2013-01-10 2013-01-10 Benzylideneguanidine Derivatives and Therapeutic Use for the Treatment of Protein Misfolding Diseases
PCT/EP2014/050422 WO2014108520A1 (en) 2013-01-10 2014-01-10 Benzylideneguanidine derivatives and therapeutic use for the treatment of protein misfolding diseases
EP14700310.7A EP2943467B1 (en) 2013-01-10 2014-01-10 Benzylideneguanidine derivatives and therapeutic use for the treatment of protein misfolding diseases

Publications (1)

Publication Number Publication Date
HRP20161208T1 true HRP20161208T1 (hr) 2016-11-04

Family

ID=47757796

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20161208TT HRP20161208T1 (hr) 2013-01-10 2014-01-10 Derivati benzilidengvanidina i terapeutska upotreba za liječenje bolesti zbog pogrešnog savijanja proteina

Country Status (21)

Country Link
US (4) US9682943B2 (en:Method)
EP (2) EP3115357B1 (en:Method)
JP (1) JP6276289B2 (en:Method)
KR (1) KR102166665B1 (en:Method)
CN (1) CN105189452B (en:Method)
AU (2) AU2014204831C1 (en:Method)
CA (1) CA2896976C (en:Method)
DK (1) DK2943467T3 (en:Method)
ES (2) ES2831453T3 (en:Method)
GB (1) GB201300435D0 (en:Method)
HR (1) HRP20161208T1 (en:Method)
HU (1) HUE030848T2 (en:Method)
IL (1) IL239629B (en:Method)
LT (1) LT2943467T (en:Method)
MX (1) MX370491B (en:Method)
PL (1) PL2943467T3 (en:Method)
PT (1) PT2943467T (en:Method)
RS (1) RS55185B1 (en:Method)
RU (1) RU2654910C2 (en:Method)
SI (1) SI2943467T1 (en:Method)
WO (1) WO2014108520A1 (en:Method)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201300435D0 (en) 2013-01-10 2013-02-27 Medical Res Council Benzylideneguanidine Derivatives and Therapeutic Use for the Treatment of Protein Misfolding Diseases
US10905663B2 (en) 2013-03-05 2021-02-02 The University Of Chicago Treatment of demyelinating disorders
RU2712452C2 (ru) * 2014-07-02 2020-01-29 Инфлектис Байосайенс Новое терапевтическое применение производных бензилиденгуанидина для лечения протеинопатий
SG11201708249SA (en) 2015-04-08 2017-11-29 Medical Res Council Methods for selecting phosphatase selective and non-selective phosphatase inhibitors
US9501793B1 (en) * 2015-06-04 2016-11-22 Herofi, Inc. Archetecture and associated methodology for data standardization and utilization in retail industry applications
WO2017021216A1 (en) * 2015-07-31 2017-02-09 Inflectis Bioscience Method of treating cancer with a combination of benzylideneguanidine derivatives and chemotherapeutic agent.
US20180230105A1 (en) 2017-01-13 2018-08-16 Regents Of The University Of Minnesota Therapeutic compounds
US11166464B2 (en) * 2017-03-06 2021-11-09 The United States Of America, As Represented By The Secretary Of Agriculture Self-assembled active agents
US20210177814A1 (en) 2018-05-09 2021-06-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of guanabenz or derivates thereof for the treatment of type i ifn-dependent pathologies
CN113072467B (zh) * 2021-03-24 2022-04-12 南方医科大学 含取代胍基衍生物及其在制备破骨细胞分化抑制剂上的应用
WO2024105168A1 (en) 2022-11-18 2024-05-23 Inflectis Bioscience Novel combinations useful for the treatments of als
US20240293343A1 (en) 2023-02-13 2024-09-05 Inflectis Bioscience Benzylideneaminoguanidine derivatives as NR2B-selective NMDA receptor antagonists and their therapeutic applications
EP4680216A1 (en) * 2023-03-16 2026-01-21 Kyoto Prefectural Public University Corporation Sephin1 and related compounds for the treatment of diseases and disorders amenable to treatment by ampk activation and/or chop inhibition

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1223492A (en) 1967-10-13 1971-02-24 American Home Prod Guanidines
US3541218A (en) * 1969-06-18 1970-11-17 Lilly Co Eli Omicron-fluorobenzylaminoguanidine for diabetes
SE7607653L (sv) 1976-07-05 1978-01-06 Haessle Ab Substituerade triazoler
JPH06510760A (ja) * 1991-08-27 1994-12-01 ジ・アップジョン・カンパニー 代謝障害および代謝の治療法
PT793646E (pt) * 1994-11-23 2002-03-28 Biovitrum Ab Carboxilatos de aminoguanidina destinados ao tratamento de diabetes mellitus nao-insulinodependente
US6335339B1 (en) 1998-01-13 2002-01-01 Scriptgen Pharmaceuticals, Inc. Triazine antiviral compounds
WO2001025192A1 (en) 1999-10-06 2001-04-12 Melacure Therapeutics Ab Guanidine derivatives and their use in the production of a medicament for blocking xanthine oxidase/dehydrogenase
GB0019357D0 (en) 2000-08-07 2000-09-27 Melacure Therapeutics Ab Novel phenyl guanidines
US6518269B1 (en) 2000-07-28 2003-02-11 University Of Arizona Foundation Cancer treatment
GB0019359D0 (en) 2000-08-07 2000-09-27 Melacure Therapeutics Ab Novel guanidines
FR2812812B1 (fr) 2000-08-08 2002-10-11 Philippe Gorny Medicament destine notamment a combattre les dysfonctions sexuelles
RU2006113941A (ru) * 2003-09-25 2007-10-27 Акадиа Фармасьютикалз Инк. (Us) Лечение невропатической боли агонистами рецептора 2 нейропептида ff
CN1875271A (zh) * 2003-09-25 2006-12-06 阿卡蒂亚药品公司 用神经肽ff受体2激动剂治疗神经痛
EP1908464A1 (en) * 2006-10-04 2008-04-09 Centre National De La Recherche Scientifique (Cnrs) Use of chlorine guanabenz derivatives for treating polyglutamine expansion associated diseases
DE602006006578D1 (de) * 2006-10-04 2009-06-10 Agronomique Inst Nat Rech Chlor enthaltende Guanabenz Derivate zur Behandlung von Prionerkrankungen
WO2008091681A2 (en) 2007-01-23 2008-07-31 Housey Gerard M Theramutein modulators
WO2011039735A2 (en) 2009-10-02 2011-04-07 Consiglio Nazionale Delle Ricerche Compounds with ddx3 inhibitory activity and uses thereof
US20130085133A1 (en) 2010-02-08 2013-04-04 Sourthern Research Institute Office of Commercialization and Intellectual Prop. Anti-viral treatment and assay to screenfor anti-viral agent
KR20130091729A (ko) 2010-07-20 2013-08-19 베스타론 코포레이션 살충제 트라이아진 및 피리미딘
WO2012048330A2 (en) * 2010-10-08 2012-04-12 The Mclean Hospital Corporation Treatment of motor neuron disease
GB201300435D0 (en) * 2013-01-10 2013-02-27 Medical Res Council Benzylideneguanidine Derivatives and Therapeutic Use for the Treatment of Protein Misfolding Diseases

Also Published As

Publication number Publication date
AU2017272151B2 (en) 2018-11-08
MX2015008977A (es) 2016-05-16
MX370491B (es) 2019-12-16
US10100020B2 (en) 2018-10-16
WO2014108520A1 (en) 2014-07-17
ES2594378T3 (es) 2016-12-19
US10954198B2 (en) 2021-03-23
CN105189452A (zh) 2015-12-23
RU2654910C2 (ru) 2018-05-25
US9682943B2 (en) 2017-06-20
AU2017272151A1 (en) 2017-12-21
US20200095210A1 (en) 2020-03-26
KR102166665B1 (ko) 2020-10-16
CN105189452B (zh) 2018-12-18
CA2896976A1 (en) 2014-07-17
PT2943467T (pt) 2016-10-18
AU2014204831B2 (en) 2017-09-07
EP2943467A1 (en) 2015-11-18
RS55185B1 (sr) 2017-01-31
AU2014204831C1 (en) 2018-04-05
US20180354914A1 (en) 2018-12-13
IL239629A0 (en) 2015-08-31
GB201300435D0 (en) 2013-02-27
BR112015016433A2 (pt) 2017-07-11
PL2943467T3 (pl) 2017-01-31
ES2831453T3 (es) 2021-06-08
DK2943467T3 (en) 2016-10-03
EP2943467B1 (en) 2016-07-13
EP3115357A1 (en) 2017-01-11
IL239629B (en) 2018-03-29
CA2896976C (en) 2021-03-02
LT2943467T (lt) 2016-10-10
US10526297B2 (en) 2020-01-07
EP3115357B1 (en) 2020-08-12
US20170247344A1 (en) 2017-08-31
SI2943467T1 (sl) 2016-11-30
HUE030848T2 (hu) 2017-06-28
KR20150127574A (ko) 2015-11-17
US20160046589A1 (en) 2016-02-18
JP6276289B2 (ja) 2018-02-07
JP2016504400A (ja) 2016-02-12
RU2015127827A (ru) 2017-01-12
AU2014204831A1 (en) 2015-07-23

Similar Documents

Publication Publication Date Title
HRP20161208T1 (hr) Derivati benzilidengvanidina i terapeutska upotreba za liječenje bolesti zbog pogrešnog savijanja proteina
JP2016504400A5 (en:Method)
HRP20180483T1 (hr) Spoj kinolona
JP2016506962A5 (en:Method)
HRP20171957T1 (hr) Derivati 2-(2,4,5-supstituiranog-anilino) pirimidina kao modulatori egfr koji su korisni za liječenje raka
FI4219508T3 (fi) Substituoitu polysyklinen pyridonijohdannainen ja sen aihiolääke
HRP20161613T1 (hr) Tvari bicikličke ureje, tioureje, gvanidina i cijanogvanidina korisne za liječenje boli
SI3024819T1 (en) Glyoxamide-substituted pyrrolamide derivatives and their use as medicines for the treatment of hepatitis B
HRP20181169T1 (hr) Predlijekovi fumarata i njihova upotreba u liječenju različitih bolesti
CY1121910T1 (el) Φαρμακευτικο παρασκευασμα που περιεχει παραγωγο διυδροκιναζολινης με αντιϊικη δραση
EA202091262A1 (ru) Пиперидиновые модуляторы рецепторов cxcr7
JP2014511892A5 (en:Method)
EA201690247A1 (ru) Аминометилбиарильные производные-ингибиторы фактора d комплемента и их применения
EA201600204A1 (ru) Производные хиназолина, фармацевтическая композиция на их основе и их применение для профилактики или лечения опухоли
SG11201901894TA (en) Anti-influenza virus pyrimidine derivatives
EA201692542A1 (ru) Индановые и индолиновые производные и их применение в качестве активаторов растворимой гуанилатциклазы
HRP20171050T1 (hr) Derivati 1,3-dihidro-2h-benzimidazol-2-ona supstituirani s heterociklima kao antivirusna sredstva za respiratorni sincicijski virus
HRP20211907T1 (hr) Pirazol – oksazolidinon spoj za anti – hepatitis b virus
EA201491525A1 (ru) Спиро[2.4]гептаны для лечения инфекций, вызванных flaviviridae
HRP20241188T1 (hr) Fenil-2-hidroksi-acetilamino-2-metil-fenil spojevi
JP2015500842A5 (en:Method)
HRP20231369T1 (hr) Inhibitori lsd1 i njihova medicinska upotreba
TR201902057T4 (tr) Tetrasiklin bileşikleri.
HRP20220231T1 (hr) Spojevi i postupci za liječenje bakterijskih infekcija
EA201692298A1 (ru) Производные карбоксамидов